GT201200180A - Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a - Google Patents

Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a

Info

Publication number
GT201200180A
GT201200180A GT201200180A GT201200180A GT201200180A GT 201200180 A GT201200180 A GT 201200180A GT 201200180 A GT201200180 A GT 201200180A GT 201200180 A GT201200180 A GT 201200180A GT 201200180 A GT201200180 A GT 201200180A
Authority
GT
Guatemala
Prior art keywords
heteroaromatic
arimidazol
derivatives
compounds
pde10a inhibitors
Prior art date
Application number
GT201200180A
Other languages
English (en)
Inventor
Jacob Nielsen
Jan Kehler
John Paul Kilburn
Mauro Marigo
Morten Langgard
Ask Puschl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201200180A publication Critical patent/GT201200180A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS HETEROAROMÁTICOS QUE SON INHIBIDORES DE ENZIMA PDE10A Y COMO TALES SON DE UTLIDAD PARA TRATAR LOS TRASTORNOS NEURODEGENERATIVOS Y PSIQUIÁTRICOS. ESPECIALMENTE, LA INVENCIÓN PROPORCIONA COMPUESTOS QUE SON ALTAMENTE SELECTIVOS PARA PDE10 RESPECTO DE OTROS SUBTIPOS DE PDE. LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE LA INVENCIÓN Y MÉTODOS PARA TRATAR TRASTORNOS UTILIZANDO DICHOS COMPUESTOS
GT201200180A 2009-12-17 2012-06-07 Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a GT201200180A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200901341 2009-12-17

Publications (1)

Publication Number Publication Date
GT201200180A true GT201200180A (es) 2015-01-16

Family

ID=44246810

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200180A GT201200180A (es) 2009-12-17 2012-06-07 Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a

Country Status (34)

Country Link
US (2) US8501797B2 (es)
EP (1) EP2513105B1 (es)
JP (1) JP5698761B2 (es)
KR (1) KR101777889B1 (es)
CN (1) CN102753551B (es)
AR (1) AR079498A1 (es)
AU (1) AU2010333437B2 (es)
CA (1) CA2783727C (es)
CO (1) CO6612246A2 (es)
CR (1) CR20120317A (es)
CY (1) CY1115278T1 (es)
DK (1) DK2513105T3 (es)
DO (1) DOP2012000168A (es)
EA (1) EA021415B1 (es)
ES (1) ES2484692T3 (es)
GE (1) GEP20156242B (es)
GT (1) GT201200180A (es)
HK (1) HK1177739A1 (es)
HR (1) HRP20140632T1 (es)
MA (1) MA33924B1 (es)
MX (1) MX2012007144A (es)
MY (1) MY158202A (es)
NZ (1) NZ600416A (es)
PL (1) PL2513105T3 (es)
PT (1) PT2513105E (es)
RS (1) RS53413B (es)
SG (1) SG181536A1 (es)
SI (1) SI2513105T1 (es)
SM (1) SMT201400114B (es)
TN (1) TN2012000287A1 (es)
TW (1) TWI481607B (es)
UA (1) UA107817C2 (es)
WO (1) WO2011072696A1 (es)
ZA (1) ZA201204418B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI481607B (zh) * 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
CN112125884A (zh) 2010-12-17 2020-12-25 诺华股份有限公司 制备嘧啶-2,4-二胺二盐酸盐的方法
CN103596929B (zh) 2010-12-17 2016-10-19 里亚塔医药公司 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮
CA2824047C (en) 2011-01-11 2019-06-18 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
EP2675791B1 (en) 2011-02-18 2016-02-17 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
RS54788B1 (sr) * 2011-08-25 2016-10-31 Merck Sharp & Dohme Inhibitori pirimidina pde10
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
WO2013107856A1 (en) * 2012-01-20 2013-07-25 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CA3041412A1 (en) * 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
CN101723941A (zh) * 2002-08-09 2010-06-09 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑
AU2003288352A1 (en) 2002-10-30 2004-06-07 Centre National De La Recherche Scientifique (Cnrs) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
US20060148838A1 (en) 2003-06-30 2006-07-06 Altana Pharma Ag Novel pyrrolodihydroisoquinolines useful in the treatment of cancer
EP1641457B1 (en) 2003-06-30 2009-08-05 Nycomed GmbH Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2005014588A1 (en) 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
EP1723134A2 (en) 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
MXPA06014236A (es) 2004-06-07 2007-02-14 Pfizer Prod Inc Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
WO2006028957A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
JP2009535394A (ja) * 2006-05-02 2009-10-01 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
WO2008006372A1 (en) * 2006-07-10 2008-01-17 H. Lundbeck A/S (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl- thiomorpholin-4-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物

Also Published As

Publication number Publication date
MX2012007144A (es) 2012-07-03
AR079498A1 (es) 2012-02-01
UA107817C2 (en) 2015-02-25
EP2513105A1 (en) 2012-10-24
PT2513105E (pt) 2014-07-31
AU2010333437A1 (en) 2012-06-21
EA021415B1 (ru) 2015-06-30
SI2513105T1 (sl) 2014-11-28
HK1177739A1 (en) 2013-08-30
CA2783727A1 (en) 2011-06-23
US8501797B2 (en) 2013-08-06
JP2013514285A (ja) 2013-04-25
TWI481607B (zh) 2015-04-21
SG181536A1 (en) 2012-07-30
GEP20156242B (en) 2015-02-10
ZA201204418B (en) 2013-08-28
PL2513105T3 (pl) 2014-09-30
KR101777889B1 (ko) 2017-09-12
RS53413B (en) 2014-12-31
CN102753551A (zh) 2012-10-24
MA33924B1 (fr) 2013-01-02
DK2513105T3 (da) 2014-07-14
HRP20140632T1 (hr) 2014-09-26
ES2484692T3 (es) 2014-08-12
TN2012000287A1 (en) 2013-12-12
EA201290518A1 (ru) 2013-01-30
JP5698761B2 (ja) 2015-04-08
CA2783727C (en) 2018-02-20
MY158202A (en) 2016-09-15
US20130289038A1 (en) 2013-10-31
KR20120123276A (ko) 2012-11-08
WO2011072696A1 (en) 2011-06-23
CN102753551B (zh) 2014-10-22
NZ600416A (en) 2013-08-30
CY1115278T1 (el) 2017-01-04
US20120302548A1 (en) 2012-11-29
TW201127831A (en) 2011-08-16
US8927738B2 (en) 2015-01-06
EP2513105B1 (en) 2014-05-14
AU2010333437B2 (en) 2016-09-01
DOP2012000168A (es) 2012-11-30
SMT201400114B (it) 2014-11-10
CR20120317A (es) 2012-08-16
CO6612246A2 (es) 2013-02-01

Similar Documents

Publication Publication Date Title
GT201200180A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
GT201200171A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
AU2018236800B2 (en) DNA-PK inhibitors
GT201300130A (es) Derivados de imidazol como inhibidores de la enzima pde10a
NI201300073A (es) Compuestos y composiciones como inhibidores de la trk
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
MX342509B (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
CR20150255A (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
ECSP12012218A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
ECSP14013148A (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CR20140107A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
IN2014DN10576A (es)
CL2019001092A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
GT201200193A (es) Derivados de aril triazol heteroarmoaticos como inhibidores de enzima pde10a
MX367425B (es) Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1.
IN2014CN03062A (es)
CL2011002946A1 (es) Compuestos derivados de tiazoltiadiazol aminopirazol, inhibidores de proteina quinasa c-met; composicion farmaceutica que los comprende y su uso en el tratamiento de diferentes tipos de cancer.
GEP201706764B (en) Quinazolin-thf-amines as pde1 inhibitors
EA201692227A1 (ru) Производные сложных аминоэфиров
ECSP14010000A (es) Derivados de quinolina como inhibidores de la enzima pde10a
ECSP15021681A (es) Derivados tricíclicos fusionados de tiofeno como inhibidores de jak
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази